FDA Accepts Supernus Pharmaceuticals' Resubmission for Parkinson's Treatment Device, Decision Expected by February 2025
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has resubmitted its new drug application for an apomorphine infusion device for Parkinson's disease to the FDA, with a decision expected by February 2025.
August 19, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals has resubmitted its NDA for an apomorphine infusion device for Parkinson's disease to the FDA, with a decision expected by February 2025.
The FDA's acceptance of the resubmission is a positive regulatory step for Supernus Pharmaceuticals. If approved, the device could address a significant need in Parkinson's disease treatment, potentially boosting the company's market position and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100